HGS-ETR1: Phase I interim data

In an ongoing open-label, dose escalation, Canadian Phase I trial, HGS-ETR1 was well tolerated at 0.01-3.0 µg/kg/week in 20 patients. Stable disease has been observed in 5 patients. Patients are curre...